The Angio Institute Research & Education Brain Health Program AngioNews/Media Joining Hands

Contributing to the Evolution of SCIENCE & WELLNESS

The study of medicine is an ongoing stream of new discoveries that continue to shape the very way we approach PROBLEM SOLVING. The Biofoundation for Angiogenesis Research and Development also known as The ANGIOFOUNDATION (501c3) funds and supports specialized clinical research projects that underscore the future of how physicians and scientists identify disorders and the resources that pave new heights in efficiency and performance with the least possible risk.

Since its official launch in Dec., 2001, the AngioFoundation was committed to conducting various disciplines of clinical research to support the advancement of technologies, treatment protocols and diagnostic science. We support research concepts and exploratory studies of minimally invasive modalities to treat cancer and inflammatory arthritis by analyzing "angiogenesis" or new blood vessel (angio) formation (genesis). Major international congresses* showed tumor blood vessel formation revealed by sonogram Doppler imaging was the best predictor of cancer aggression. Treatment success is validated when abnormal arteries decrease in number after therapy. Treatment failure may be demonstrated earlier with this test allowing alternate therapies to be applied. The AngioFoundation has also expanded its research work through collaboration with global technology developers or modern laser innovations, MRI's & ultrasound technologies to detect and treat prostate, breast, thyroid and skin cancers non-invasively. The AngioFoundation's public mission is to advance image guided diagnostic and therapeutic technologies worldwide and supports teaching programs for physicians on new modalities to diagnose and deliver therapies for cancer and allied diseases including inflammatory arthritis.

* (AIUM2019 ICIS2018, ASLMS2019 and RSNA2018)



Research & Educational PROGRAMS
The AngioFoundation has been recognized worldwide by official medical organizations and peer reviews for its work in FIVE MAIN focal topics and class divisions. We continually maintain and update research works in these categories to support the advancement of these disciplines as part of The AngioFoundation's commitment to the scientific community.

DIAGNOSTIC PROGRESS: Global support of the advanced use of modern Diagnostic Imaging technologies to identify all health issues - including the development of new protocols and the support of new modalities. PUBLISHING all findings, reviews and direct-from- professional field research about all therapeutic and diagnostic processes. Academic exchange through web-based distribution for the medical and patient communities. TECH REVIEW: Beta-testing, industry-wide comparative feature review/evaluation program. Evaluation of upcoming designs entering the public market leading to an independent public report of all non-invasive medical and health innovations. OCCUPATIONAL HEALTH HAZARDS: Internal study of all work-related illnesses including chronic disorders and predispositions from victims associated with all first responders exposed to disaster-related rescue calls. Collaboration environmental statistics. EXPLORATORY LAB SCIENCE: Case studies of domestic and foreign health solutions of all laser-based medical equipment including devices specializing in sub-dermal musculatory treatment of chronic disorders.

AIUM NEWS: DR. ROBERT BARD ELECTED IN 6-YEAR LEADERSHIP ROLES WITH NATIONAL ULTRASOUND ASSOCIATION 7/28/2022 - Members of the American Institute of Ultrasound in Medicine (AIUM) have elected a new slate of leaders to the Executive Committee, Board of Governors, and Communities. These leaders will work to support the AIUM’s mission to empower and cultivate a global multidisciplinary community engaged in the use of medical ultrasound through raising awareness, education, sharing information, and research. DR. ROBERT L. BARD (Diagnostic Imaging Specialist, NYC) was recently elected Secretary of the Therapeutic Ultrasound Community. He will serve a 2-year term as Secretary, a 2-year term as Vice Chair, and a 2-year term as Secretary. The AIUM's mission is to empower and cultivate a global multidisciplinary community engaged in the use of medical ultrasound through raising awareness, education, sharing information, and research. "The AIUM values the individual members who volunteer their time, talents, and expertise to ensure we address the needs of the ultrasound community," said AIUM CEO Glynis Harvey, CAE. "Dr Bard joins a leadership team dedicated to improving the value of the AIUM and we look forward to his contributions."